Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging

Clinical Breast Cancer

Volumn 10, Issue 2, 2010, Pages 113-118

  Chéreau, Elisabeth ^a   Uzan, Catherine ^a   Balleyguier, Corinne ^a   Chevalier, Julie ^a   De Paillerets, Brigitte Bressac ^a   Caron, Olivier ^a   Rimareix, Françoise ^a   Mathieu, Marie Christine ^a   Koskas, Martin ^a   Bourgier, Céline ^a   André, Fabrice ^a   Dromain, Clarisse ^a   Delaloge, Suzette ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Aggressive tumor phenotype; Axillary lymphadenectomy; Germline mutation; Intensive screening; Nodal involvement

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GADOLINIUM CHELATE; GADOTERATE MEGLUMINE; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GENE MUTATION; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; TUMOR VOLUME;

EID: 77950473754     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.022     Document Type: Article

References (34)

1. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008; 299:194-201.
2. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60:1013-1020
3. Rebbeck TR, Domchek SM. Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2008; 10:108.
4. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98:1694-1706
5. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159-164 (Pubitemid 32662123)
6. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469-8476 (Pubitemid 46260243)
7. Kriege M, Brekelmans CT, Peterse H, et al. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 2006; 102:357-363 (Pubitemid 46474846)
8. Pichert G, Bolliger B, Buser K, et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003; 14:9-19. (Pubitemid 36150253)
9. Vasen HF, Haites NE, Evans DG, et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: A survey among 16 European family cancer clinics-European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34:1922-1926
10. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2-Cancer Genetics Studies Consortium. JAMA 1997; 277:997-1003. (Pubitemid 27142370)
11. Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148:671-679 (Pubitemid 351669112)
12. Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995; 196:593-610.
13. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295:2374-2384 (Pubitemid 43788105)
14. Lee JM, Kopans DB, McMahon PM, et al. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging-Markov Monte Carlo decision analysis. Radiology 2008; 246:763-771
15. Eisinger F, Bressac B, Castaigne D, et al. Identification and management of hereditary predisposition to cancer of the breast and the ovary. Bull Cancer 2004; 91:219-237 (Pubitemid 39158743)
16. Erguvan-Dogan B, Whitman GJ, Kushwaha AC, et al. BI-RADS-MRI: a primer. AJR Am J Roentgenol 2006; 187:152-160
17. Vennin P, Giard S, Julian-Reynier C, et al. Attitudes towards screening and prevention of breast and ovarian cancers with hereditary predisposition. Survey by female gynecologists in the north of France. Bull Cancer 1996; 83:697-702. (Pubitemid 26300490)
18. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24:5652-5657 (Pubitemid 46631305)
19. Evans AJ, Rakha EA, Pinder SE, et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J Med Screen 2007; 14:210-214
20. Foulkes WD, Grainge MJ, Rakha EA, et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat; 2009; 117:199-204.
21. Loman N, Johannsson O, Bendahl P, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 2000; 36:1365-1373 (Pubitemid 30421140)
22. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1095-1102 (Pubitemid 32717542)
23. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292:1317-1325 (Pubitemid 39223222)
24. Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43:1905-1917 (Pubitemid 47299201)
25. Yu J, Park A, Morris E, et al. MRI screening in a clinic population with a family history of breast cancer. Ann Surg Oncol 2008; 15:452-461
26. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103:1898-1905 (Pubitemid 40563263)
27. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427-437
28. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769-1778 (Pubitemid 40744657)
29. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007; 242:698-715. (Pubitemid 46310082)
30. Brekelmans CT, Seynaeve C, Bartels CC, et al; Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19:924-930 (Pubitemid 32176266)
31. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20:1260-1268 (Pubitemid 34177432)
32. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100:2079-2083
33. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007; 13:7357-7362
34. Seewaldt VL, Scott V. Rapid progression of basal-type breast cancer. N Engl J Med 2007; 356:e12.